scholarly journals Caval Valve Implantation for Treatment of Severe Tricuspid Regurgitation

2018 ◽  
Vol 71 (10) ◽  
pp. 1183-1184 ◽  
Author(s):  
Alexander Lauten ◽  
Henryk Dreger ◽  
Joachim Schofer ◽  
Eberhard Grube ◽  
Frederik Beckhoff ◽  
...  
Keyword(s):  
Tricuspid Regurgitation ◽  
Severe Tricuspid Regurgitation ◽  
Valve Implantation

scholarly journals Heterotopic caval valve implantation for the management of severe tricuspid regurgitation: a case series

2020 ◽  
Author(s):  
Aidan Sharkey ◽  
Ronny Munoz Acuna ◽  
Kiran Belani ◽  
Ravi K Sharma ◽  
Omar Chaudhary ◽  
...  
Keyword(s):  
Medical Therapy ◽  
Tricuspid Regurgitation ◽  
Surgical Intervention ◽  
Symptom Relief ◽  
Vena Cava ◽  
Case Series ◽  
High Morbidity ◽  
Severe Tricuspid Regurgitation ◽  
Maximal Medical Therapy ◽  
Valve Implantation

Abstract Background Severe tricuspid regurgitation (TR) is a complex condition that can be difficult to treat medically, and often surgical intervention is prohibited due to the high morbidity and mortality associated with this intervention. In patients who have failed maximal medical therapy and have progressive symptoms related to their severe TR, heterotopic caval valve implantation (CAVI) offers potential for symptom relief for these patients. Case summary We present two cases of patients with severe TR with symptoms of heart failure that were refractory to medical therapy. Due to extensive comorbidities in these patient’s surgical intervention was deemed unsuitable and the decision was made to proceed with heterotopic CAVI in order to try and control their symptoms. Both patients successfully underwent the procedure and had an Edwards SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA, USA) implanted in the inferior vena cava/right atrium junction. In both patients, there was improvement in the postoperative haemodynamics as measured by invasive and non-invasive methods. Successful discharge was achieved in both patients with improvement in their symptoms. Discussion Selective use of heterotopic CAVI to treat symptomatic severe TR that is refractory to medical therapy may be a viable option to improve symptoms in those patients that are unsuitable for surgical intervention.

scholarly journals Inferior Caval Valve Implantation Versus Optimal Medical Therapy for Severe Tricuspid Regurgitation

2019 ◽  
Vol 74 (3) ◽  
pp. 473-475 ◽  
Author(s):  
Michael Laule ◽  
Isabel Mattig ◽  
Christoph Schöbel ◽  
Fabian Knebel ◽  
Alexander Lauten ◽  
...  
Keyword(s):  
Medical Therapy ◽  
Tricuspid Regurgitation ◽  
Optimal Medical Therapy ◽  
Severe Tricuspid Regurgitation ◽  
Valve Implantation

scholarly journals TRANSCATHETER CAVAL VALVE IMPLANTATION FOR SEVERE TRICUSPID REGURGITATION

2019 ◽  
Vol 73 (9) ◽  
pp. 2277
Author(s):  
Enrique Padilla Campos ◽  
Brian Hachey ◽  
Scott Hurley ◽  
Rohan Mehta ◽  
Anahita Shahrrava ◽  
...  
Keyword(s):  
Tricuspid Regurgitation ◽  
Severe Tricuspid Regurgitation ◽  
Valve Implantation

scholarly journals Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

2021 ◽  
Vol 10 (19) ◽  
pp. 4601
Author(s):  
Omar Abdul-Jawad Altisent ◽  
Rimantas Benetis ◽  
Vaida Mizarien ◽  
Francisco Gual-Capllonch ◽  
Eduard Fernandez-Nofrerias ◽  
...  
Keyword(s):  
Tricuspid Regurgitation ◽  
Heart Surgery ◽  
Open Heart Surgery ◽  
Feasibility Studies ◽  
Heart Valve Disease ◽  
Current Evidence ◽  
High Morbidity ◽  
Suitable Alternative ◽  
Severe Tricuspid Regurgitation ◽  
Valve Implantation

Severe tricuspid regurgitation remains a challenging heart-valve disease to effectively treat with high morbidity and mortality at mid-term. Currently guideline-directed medical treatment is limited to escalating dose of diuretics, and the rationale and timing of open-heart surgery remains controversial. Emerging percutaneous therapies for severe tricuspid regurgitation continue to show promising results in early feasibility studies. However, randomized trial data is lacking. Additionally, many patients are deemed unsuitable for these emerging therapies due to anatomical or imaging constraints. Given the technical simplicity of the bicaval valve implantation (CAVI) technique compared to other transcatheter devices, CAVI is postulated as a suitable alternative for a wide variety of patients affected with severe+ tricuspid regurgitation. In this review we illustrate the current evidence and ongoing uncertainties of CAVI, focusing on the novel CAVI-specific devices.

scholarly journals Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bernd Hewing ◽  
Isabel Mattig ◽  
Fabian Knebel ◽  
Verena Stangl ◽  
Michael Laule ◽  
...  
Keyword(s):  
Tricuspid Regurgitation ◽  
Vena Cava ◽  
Clinical Signs ◽  
Hepatic Function ◽  
Venous Congestion ◽  
Abdominal Circumference ◽  
Severe Tricuspid Regurgitation ◽  
Edwards Sapien ◽  
Valve Implantation

AbstractDue to progressive abdominal-venous congestion severe tricuspid regurgitation (TR) is a common cause of cardiorenal and cardiohepatic syndrome. We initiated the TRICAVAL study to compare interventional valve implantation into the inferior vena cava (CAVI) versus optimal medical therapy (OMT) in severe TR. In the present subanalysis, we aimed to evaluate the effects of CAVI on clinical signs of congestion, renal and hepatic function. TRICAVAL was an investigator-initiated, randomized trial. Twenty-eight patients with severe TR were randomized to OMT or CAVI using an Edwards Sapien XT valve. Probands who completed the 3-month follow-up (CAVI [n = 8], OMT [n = 10]) were evaluated by medical history, clinical examination, and laboratory testing at baseline, 3 and 12 months. After 3 months, the CAVI group exhibited a significant reduction of body weight (from 80.7 [69.0–87.7] kg to 75.5 [63.8–84.6] kg, p < 0.05) and abdominal circumference (from 101.5 ± 13.8 cm to 96.3 ± 15.4 cm, p ≤ 0.01) and a trend to lower doses of diuretics compared to OMT. Renal and hepatic function parameters did not change significantly. Within a short-term follow-up, CAVI led to an improvement of clinical signs of venous congestion and a non-significant reduction of diuretic doses compared to OMT.

scholarly journals Feasibility of Transcatheter Caval Valve Implantation to Improve Sleep-Disordered Breathing in Patients With Severe Tricuspid Regurgitation—A Pilot Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Youmeng Wang ◽  
Roberto Fernandes Branco ◽  
Andrea Fietzeck ◽  
Thomas Penzel ◽  
Christoph Schöbel
Keyword(s):  
Heart Failure ◽  
Tricuspid Regurgitation ◽  
Sleep Disordered Breathing ◽  
Right Heart Failure ◽  
Right Heart ◽  
Severe Tricuspid Regurgitation ◽  
Laboratory Results ◽  
Echocardiographic Parameters ◽  
Valve Implantation

Transcatheter caval valve implantation (CAVI) has been evaluated as a treatment option for inoperable patients with severe symptomatic tricuspid regurgitation (TR). We studied the effect of CAVI on sleep disorder breathing (SDB) in patients with right heart failure and TR. Twenty right heart failure patients with severe symptomatic TR who underwent portable monitoring of SDB (ApneaLink), echocardiography, cardiopulmonary exercise (CPET), and laboratory testing were enrolled. This was a single-center, nonblinded study. There were no significant changes in sleep variables, echocardiographic parameters, laboratory results, lung function, and CPET after CAVI. In conclusion, these data suggest that CAVI may not have an effect on SDB; however, additional follow-up fully powered studies with appropriate statistical analyses are needed.

Sign in / Sign up

Export Citation Format

Share Document